Methods of treating or preventing inflammation and hypersensitivity with oxidative reductive potential water solution

Inventors

Alimi, Hojabr • Gutiérrez, Andrés

Assignees

Microsafe Group Dmcc

Abstract

Provided is a method for preventing or treating inflammation and associated states (e.g. infection, hypersensitivity, pain) by administering a therapeutically effective amount of an oxidative reduction potential (ORP) water solution that is stable for at least about twenty-four hours. The ORP water solution administered in accordance with the invention can be combined with one or more suitable carriers and can be administered in conjunction with one or more additional therapeutic agents.

Core Innovation

The document describes methods to prevent or treat inflammation and hypersensitivity by administering an oxidative reductive potential (ORP) water solution, also termed super-oxidized water (SOW). The solution is characterized as stable for at least two months, has a pH of about 6.4 to about 7.8, and comprises a mixture of cathode water and anode water. The ORP water solution further comprises free chlorine species at a level of about 10 ppm to about 400 ppm, with the free chlorine species selected from hypochlorous acid, hypochlorite ions, sodium hypochlorite, chlorite ions, dissolved chlorine gas, and mixtures thereof.

The document states that inhibition of mast cell degranulation is used to treat atopic dermatitis, including atopic dermatitis as a hypersensitivity condition. It further describes a mechanism in which the ORP water solution non-selectively reduces mast-cell pro-inflammatory cytokine secretion, including TNF-α, MIP1-α, IL-6, and IL-13, while not altering cytokine mRNA. The described activity is presented as broadly anti-inflammatory and as addressing inflammation and hypersensitivity.

The solution is also described as excluding an antibiotic. In addition to the therapeutic concept, the document describes formulation and stability as part of the invention, including the ORP solution being stable for at least two months. The document also includes administration routes stated for the ORP water solution, including topical, parenteral, endoscopic, and mucosal routes, with spray, mist, aerosol, and steam described as delivery modalities.

Claims Coverage

The only independent claim identified is directed specifically to treating atopic dermatitis using a therapeutically effective ORP water solution. Across the claims mentioned in the partial content, the inventive coverage centers on solution stability and formulation parameters, mast cell degranulation inhibition, absence of an antibiotic, and refinement of administration modality and condition context.

Overall, the claim coverage focuses on using a stable oxidative reductive potential water solution composed of cathode/anode water with a defined pH and specified free chlorine species levels to inhibit mast cell degranulation and thereby treat atopic dermatitis, while explicitly excluding antibiotics. Dependent claim refinements further narrow formulation and delivery, including topical administration to cutaneous/subcutaneous tissue and characterizing atopic dermatitis as infection-caused.

Stated Advantages

Documented Applications